HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CIR compendium

This article was originally published in The Rose Sheet

Executive Summary

The 2007 edition of the Cosmetic Ingredient Review's ingredient safety compendium - containing safety assessments of over 1,300 individual cosmetic ingredients - is now available, the review panel announces. The volume identifies 784 ingredients that are safe for cosmetic formulations, 408 that are safe if "qualifications are heeded," 119 with insufficient safety data and nine unsafe ingredients, according to CIR's March 23 release. The new edition features a separate listing for ingredients that have been re-reviewed since their initial evaluation in the early 1980s. CIR was established by CTFA in 1976 to provide independent assessments of cosmetic ingredients. The group most recently reopened its assessment of the botanical extract Calendula officinalis (1"The Rose Sheet" Dec. 11, 2006, p. 7)...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS014604

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel